Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients who have histologically and/or cytologically confirmed solid tumors requiring treatment.~2. Patients with solid tumors which are resistant to approved conventional anti-tumor therapies, or for which no appropriate treatment is available.~3. Patients who had completed all previous treatments (including surgery and radiotherapy) and supportive care (such as transfusion of blood, blood components and granulocyte colony-stimulating factor \[G-CSF\] treatment) at least 4 weeks before registration, and no sign or symptom of acute toxicity occurred in previous treatments.~4. Patients 20 years or older and less than 75 years of age at the time of registration.~5. Patients with 0 or 1 Performance Status (PS) established by Eastern Cooperative Oncology Group (ECOG.)~6. Patients who can stay in hospital for more than 1 cycle of treatment.~7. Patients who are expected to survive for more than 3 months from the start of study drug administration.~8. Patients who have provided written informed consent for the participation in the study.~Exclusion criteria:~1. Patients with clinical symptoms due to brain metastases requiring treatment.~2. Patients who have any of the following laboratory test findings:~   1. Hemoglobin less than 9.0 g/dL~  2. Neutrophil count less than 1.5 x 10 9/L~  3. Platelet count less than 100 x 10 9/L~  4. Serum bilirubin greater than 1.5 mg/dL~  5. AST, ALT greater than 100 IU/L~  6. Serum creatinine greater than 1.5 mg/dL or creatinine clearance less than 50 mL/minute~3. Patients with positive reaction for human immunodeficiency virus (HIV) or hepatitis virus C (HCV) antibody or hepatitis B virus surface (HBs) antigen, or patients with untreated serious infections.~4. Patients with clinically significant cardiac disorders or unstable ischemic heart diseases including myocardial infarction within six months before the registration for the study.~5. Patients with marked Baseline prolongation of QT/QTc interval (QTc interval greater than 450 msec for males or greater than 470 msec for females) using the Fridericia method for QTc analysis.~6. Patients with hemorrhagic or thrombotic diseases or who are using therapeutic doses of anticoagulants such as aspirin, warfarin, or ticlopidine.~7. Patients who are diagnosed with hypertension (defined as repeatedly measured blood pressure = 160/90 mmHg) at Screening, irrespective of use of antihypertensive drugs.~8. Patients who have proteinuria greater than 1 on bedside testing.~9. Patients who have history of insufficient gastrointestinal absorption, or patients who received gastric or intestinal anastomoses within 4 weeks before registration.~10. Patients who have history of alcoholism, drug addiction or mental or physical disorders, which, in the investigators opinion, may impair study compliance.~11. Patients who received any investigational drug within 30 days before the registration of the study.~12. Patients who received CYP3A4 inhibitors including itraconazole, erythromycin, clarithromycin, diltiazem or verapamil during screening and who have to use these drugs during the study.~13. Pregnant or nursing patients (all female patients with pregnancy potential must have negative pregnancy test performed before registration, and post-menopausal women must be amenorrheic for at least 12 months.) Female patients must use appropriate contraception.~14. Fertile male patients who refuse to use contraception, or whose female partners are not using appropriate contraception.~15. Patients who are judged by the investigator to be inappropriate for the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete